Search

As Opill—the first over-the-counter daily oral contraceptive pill in the United States—is expected to be available for purchase in early 2024, new research conducted by KFF examines barriers to its accessibility for consumers and challenges in providing insurance coverage for it. Based on interviews with nearly 80 representatives from private…

This map presents the share of Title X clinics that are Planned Parenthood clinics and/or provide abortions (as of 05/2019) and would no longer qualify for funding unless they separate from Planned Parenthood Federation of America or physically separate their abortion services from their family planning care.

In a new brief, KFF examines how the Comstock Act, an 1873 anti-vice law banning the mailing of obscene matter and articles, could be used by an anti-abortion presidential administration to sharply restrict the availability of abortion nationwide.  The Biden Administration’s Department of Justice has said the Comstock Act should…

KFF recently updated its interactive dashboard with national and state data on women’s health, as well as information about various policies that affect women’s health. The dashboard provides instant access the most up-to-date state level indicators of women’s health in the U.S. Many of the indicators also provide national and…

This data collection draws on Medicare and Medicaid administrative data to present national and state-level information on people who are covered by both Medicare and Medicaid, referred to as dual-eligible individuals (also known as dually-enrolled beneficiaries).

A new KFF survey of office-based OBGYNs finds widespread effects on their practices and patients since the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization one year ago.  In states with abortion bans, half say that they have patients who have been unable to obtain an abortion, about…

Following the Supreme Court’s ruling overturning Roe v. Wade, uncertainty has emerged over whether the right to contraception could also be limited. Justice Thomas’ concurring opinion in Dobbs renewed attention and raised the possibility that other Supreme Court precedents relying on the same principles as Roe, such as the right…

With federal regulators seeking public input on the potential benefits, costs, and implementation considerations of requiring private health insurance plans to cover over-the-counter preventive products without a prescription, a new KFF post explores the issues relevant to covering over-the-counter contraceptives. These contraceptives include Opill, the first daily oral contraceptive pill…

Nearly a year after the Supreme Court overturned Roe v. Wade, this poll examines the public’s views of abortion and the Supreme Court, and knowledge about mifepristone, a medication abortion drug that is the subject of another court case, the ACA’s preventive services provision and HIV in the US.

More than six months since the Supreme Court issued their Dobbs decision which overturned Roe v. Wade, there is widespread public confusion about the medication abortion pill and whether it is legal at the state level, according to the latest KFF Health Tracking Poll. The poll also finds many are…